Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Polynovo ( (AU:PNV) ) just unveiled an announcement.
PolyNovo Limited has requested a trading halt on its securities pending the release of an announcement related to a clinical trial. The trial investigates the effectiveness of NovoSorb BTM combined with negative pressure wound therapy compared to standard care in treating neuroischemic diabetic wounds. This announcement could have significant implications for PolyNovo’s market positioning and stakeholder interests, as it pertains to the potential efficacy of their product in a critical area of wound care.
The most recent analyst rating on (AU:PNV) stock is a Hold with a A$1.50 price target. To see the full list of analyst forecasts on Polynovo stock, see the AU:PNV Stock Forecast page.
More about Polynovo
PolyNovo Limited operates in the medical technology industry, focusing on developing and commercializing innovative wound care solutions. Their primary product, NovoSorb BTM, is used in the treatment of complex wounds, and the company is known for its emphasis on improving patient outcomes.
Average Trading Volume: 2,677,259
Technical Sentiment Signal: Sell
Current Market Cap: A$967.2M
For an in-depth examination of PNV stock, go to TipRanks’ Overview page.